Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes

27 May 2025

Abstract excerpt

Anemia is the primary clinical manifestation of myelodysplastic syndromes (MDSs), but the molecular pathogenesis of ineffective erythropoiesis remains incompletely understood. Luspatercept, an activin receptor 2B (ACVRIIB-Fc) ligand trap, has been approved to treat anemia; however, its molecular mechanism of action is unclear. We found that activin receptor 2B (ACVR2B), its ligand growth and differentiation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to RNA regulation and disease
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40424086
DOI: 10.1172/jci189266

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromesPMID 40424086Read ↗

Smad2/3‐pathway ligand trap luspatercept enhances erythroid differentiation in murine β‐thalassaemia by increasing GATA‐1 availabilitySemantic proximity Read ↗

Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromesSemantic proximity Read ↗

A CRISPR-Based Humanized Model Reveals Cooperative Role of STAG2 Loss in Familial GATA2-Deficient MDS ProgressionSemantic proximity Read ↗

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromesSemantic proximity Read ↗

Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes.Semantic proximity Read ↗

Myelodysplastic syndromes with ring sideroblasts.Semantic proximity Read ↗

Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice.Semantic proximity Read ↗

SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromesSemantic proximity Read ↗

SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing.Semantic proximity Read ↗

Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.Semantic proximity Read ↗

Azacitidine Response in Myelodysplastic Syndromes is Marked by NK-like CD8 T-Cell Expansion and CXCL12+ Reticular Cell RemodelingSemantic proximity Read ↗

Epigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic TargetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.